Q2 FY2026 · ended Jun 30, 2026 · Revenue $0 · Filed Aug 11, 2026
SELLAS Life Sciences Group, Inc. (SLS) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $0 and a net loss of $9.6 million. As of Jun 30, 2026 it held $138.3 million in cash and investments and $737,000 in total debt.
Revenue
$0
Net income
$-9.61M
-45.5% vs year-ago quarter
Operating cash flow
$-7.59M
-3.5% vs year-ago quarter
Free cash flow
—
EPS
$-0.05
+28.6% vs year-ago quarter
Dividend per share
None
Shares outstanding
201.95M
+91.8% vs year-ago quarter
Net cash
$137.61M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SLS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1390478
- Former names
- GALENA BIOPHARMA, INC. (until Dec 15, 2017); Galena Biopharma, Inc. (until Dec 15, 2017); RXI PHARMACEUTICALS CORP (until Sep 21, 2011)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | — | — | — | — |
| Operating income | -$10.6M | -$9.3M | -$8.3M | -$7.1M | -$6.9M |
| Net income | -$9.6M | -$8.4M | -$7.7M | -$6.8M | -$6.6M |
| Diluted EPS | -$0.05 | -$0.05 | -$0.05 | -$0.06 | -$0.07 |
| Operating cash flow | -$7.6M | -$8.8M | -$4.9M | -$7.1M | -$7.3M |
| Total assets | $145.4M | $114.2M | $78.3M | $51.6M | $32.3M |
| Total liabilities | $7.7M | $6.8M | $7.5M | $5.9M | $6.2M |
| Stockholders' equity | $137.7M | $107.4M | $70.9M | $45.6M | $26.1M |
| Cash and investments | $138.3M | $107.1M | $71.8M | $44.3M | $25.3M |
| Total debt | $737,000 | $871,000 | $1.0M | $599,000 | $737,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Other events
|
Jul 27, 2026 | Jul 24, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 25, 2026 | Jun 24, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 18, 2026 | Jun 16, 2026 |
| 8-K |
Current report
Other events
|
Jun 2, 2026 | Jun 2, 2026 |
All 1002 SELLAS Life Sciences Group, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.